Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity

ABSTRACT

Amide, sulfonamide and urea compounds having an inhibitory effect on Src kinase including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formulae I and II:

[0001] This application claims the benefit of U.S. ProvisionalApplication No. 60/304,020, filed Jul. 09, 2001.

FIELD OF THE INVENTION

[0002] The present invention discloses novel substituted amidecompounds, specifically carboxamides, sulfonamides, and urea compoundshaving enzyme inhibiting properties, especially for inhibiting proteintyrosine kinases.

BACKGROUND OF THE INVENTION

[0003] The novel compounds of the present invention may have generaltherapeutic value for the treatment of such diseases as cancer,including bone, colon or breast cancer; immunodeficiency disorders anddiabetes; atherosclerosis, osteoporosis, leukemia and other conditionssuch as coronary heart disease, congestive heart failure, renal failureand diseases of the central nervous system where the compounds exert abeneficial effect. The inventive compounds have been found to inhibitthe Src protein tyrosine kinase, a member of the Src family.

[0004] The Src family consists of nine members—Src. Yes, Fgr, Yrk. Fyn.Lyn, Hck, Lck and Blk—which share the same domain structure. TheN-terminal, unique domain contains a myristylation site and frequently apalmitoylation site. It is followed by the regulatory SH3 and SH2domains, a catalytic domain that is bilobal and has its active sitewedged between the two lobes, and a C-terminal regulatory tail thatcontains the hallmark regulatory tyrosine residue (Tyr527 in Src).Kinase activity is reduced when the latter is phosphorylated and boundto the SH2 domain. The SH2 and SH3 domains bind phosphotyrosyl andproline-rich peptides, respectively: through these interactions, theyparticipate in intra- and intermolecular regulation of kinase activity,as well as localization and substrate recognition.

[0005] There is a wealth of evidence that tyrosine phosphorylation playsa crucial role in many cell regulatory processes. Fahad Al-Obeidi etal., Biopolymers (Peptide Science) 47, 197-223 (1998). Researchers havefound that functional perturbation of the kinases results in manydiseases. Thus, there has been a great deal of effort applied inattempts to develop potent and selective inhibitors for these enzymes.

[0006] The Src protein tyrosine kinase plays a role in osteoporosis andother bone diseases. Osteoporosis is defined as a systemic skeletaldisease which is characterized by low bone mass and microarchitecturaldeterioration of bone tissue resulting in an increase in bone fragilityand susceptibility to fracture, W. A. Peck, et al., Am. J. Med., 94,646, (1993) Conference Report. It is estimated that osteoporosis causes1.5 million fractures annually with a total medical cost of $13.8billion. National Osteoporosis Foundation, August, 1997. The mosttypical sites of such fractures are the hip, spine, wrist, and ribs. Itis also estimated that one out of every two women and one in eight menwill have an osteoporosis related fracture in their lifetime.Osteoporosis is most commonly associated with postmenopause andage-related bone tissue loss. In addition, osteoporosis can occursecondarily to various drugs and diseases such as corticosteroids,anticonvulsants, alcohol, malabsorption syndromes, primary biliarycirrhosis, myeloma, thalassemia, thyrtoxicosis, Cushing's syndrome,Turner's syndrome, and primary hyperparathyroidism. Drugs used in thetreatment of osteoporosis are generally classified as antiresorptive orformation stimulating. In normal bone tissue, there is a balance betweenbone formation by osteoblasts and bone resorption by osteoclasts. Whenthe balance of this ongoing process is upset, bone resorption can exceedbone formation resulting in quantitative bone loss. Most of thetreatments have involved those that act through inhibition of boneresorption, such as calcium supplements, estrogen, calcitonin, andvitamin D, L. Riggs, West. J Med., 154, 63 (1991).

[0007] Examples of treatments which act though stimulation of boneformation are sodium fluoride, low intermittent dosage of parathyroidhormone, M. Missbach, et al., Rech. Chimie Med., July, 1997, London.

[0008] Several reports have disclosed compelling evidence that theprotein tyrosine kinase (PTK)p6Oc-Src (sometimes referred to as c-Src)plays a critical role in osteoclastic function, M. Missbach, et al.,ibid. It was reported that, in vitro, kinase inhibitors of c-Src arecapable of reducing osteoclastic bone resorption, Ibid. Osteoclasts arebone marrow cells that are responsible for breaking down or remodelingbone. Once an osteoclast comes into contact with the bone surface, itadheres tightly to the bone, flattens out, and begins the process ofsecreting materials which results in dissolution of the bone. Thisfundamental action of osteoclasts is dependent on Src kinase. In thiscase it is clear that at least one of the roles for Src kinase is in theregulation of cytoskeletal changes involved in establishing the closebone cell interface and in polarizing cellular secretion toward the bonesurface. Thus, animals genetically engineered to lack Src kinase showabnormalities that indicate a general inability to resorb bone.

[0009] In addition, osteoclasts derived from these animals are unablethe to flatten on bone, nor are they able to dissolve it. Consistentwith these results, small molecule inhibitors of Src kinase have beenshown to be useful in countering bone loss in animal models ofosteoporosis, such as IL-1-induced hypercalcemia, and bone loss inovariectomized rats. Src kinase inhibitors would be useful for thetreatment of disorders marked by inappropriate bone resorption likeosteoporosis.

SUMMARY OF THE INVENTION

[0010] The present invention provides novel carboxamides, sulfonamidesand ureas having inhibitory activity against osteoporosis and relatedbone tissue loss.

[0011] In one embodiment, this invention provides novel carboxamidecompounds having such desirable therapeutically inhibitory activity. Theinventive carboxamides have the general structure shown in Formula I,including enantiomers, stereolsomers and tautomers thereof, orpharmaceutically acceptable salts or solvates of said compound, saidcompound having the general structure shown in Formula I:

[0012] wherein:

[0013] m is an integer from 0 to 4;

[0014] n is an integer from 1 to 6;

[0015] R′ is a C₁-C₄ alkyl;

[0016] R₁ is:

[0017] R₃ is selected from the group consisting of H, C₁-C₄ straightchain alkyl and C₁-C₄ branched alkyl;

[0018] R₂ is selected from the group consisting of—(CH₂)_(p)—NH—C(═NH)NH₂; —(CH₂)_(p)—R₄; and —(CH₂)_(q)—Ar₁, wherein p isan integer from 1 to 4; q is 0 or 1; R₄ is C₅-C₇ cycloalkyl; and Ar₁ isselected from the group consisting of:

[0019] wherein

[0020] R₅ is —NH₂ or phenyl.

[0021] In another embodiment, this invention provides novel substitutedurea and sulfonamide compounds having inhibitory activity againstosteoporosis and related bone tissue loss. The inventive compounds havethe general structure shown in Formula II, including enantiomers,stereoisomers and tautomers thereof, as well as its pharmaceuticallyacceptable salts or solvates:

[0022] wherein

[0023] R₁ is selected from the group consisting of H, straight chainC₁-C₆ alkyl; branched C₁-C₆ alkyl; —(CH₂)_(p)—Ar₁; and —(CH₂)_(p)—R₄,wherein p is 1 or 2;

[0024] Ar₁ is phenyl or naphthyl optionally substituted with a straightchain or branched C₁-C₆ alkyl group; and

[0025] R₄ is C₅-C₇ cycloalkyl;

[0026] R₂ is selected from the group consisting of:

[0027] R₅ is selected from the group consisting of H, straight chainC₁-C₆ alkyl;

[0028] branched C₁-C₆ alkyl;

[0029] R₃ is —(CH₂)_(q)—Ar₂ or (CH═CH)-Phenyl, wherein q is an integerfrom 0 to 4; and Ar₂ is selected from the group consisting of:

[0030] Y is selected from the group consisting of:

[0031] with the proviso that when Y is any of the moieties:

[0032] then R₁ is H.

[0033] When used herein, unless otherwise defined, the following termshave the given meanings:

[0034] alkyl (including the alkyl portions of lower alkoxy)—represents astraight or branched, saturated hydrocarbon chain having from 1 to 10carbon atoms, preferably from 1 to 6;

[0035] aryl—represents a carbocyclic group having from 6 to 14 carbonatoms and having at least one benzenoid ring, with all availablesubstitutable aromatic carbon atoms of the carbocyclic group beingintended as possible points of attachment. Preferred aryl groups include1-naphthyl, 2-naphthyl and indanyl, and especially phenyl andsubstituted phenyl;

[0036] aralkyl—represents a moiety containing an aryl group linked viala lower alkyl;

[0037] alkylaryl—represents a moiety containing a lower alkyl linked viaan aryl group;

[0038] cycloalkyl—represents a saturated carbocyclic ring having from 3to 8 carbon atoms, preferably 5 or 6, optionally substituted.

[0039] heterocyclic—represents, in addition to the heteroaryl groupsdefined below, saturated and unsaturated cyclic organic groups having atleast one O, S and/or N atom interrupting a carbocyclic ring structurethat consists of one ring or two fused rings, wherein each ring is 5-,6- or 7-membered and may or may not have double bonds that lackdelocalized pi electrons, which ring structure has from 2 to 8,preferably from 3 to 6 carbon atoms, e.g., 2- or 3-piperidinyl, 2- or3-piperazinyl, 2- or 3-morpholinyl, or 2- or 3-thiomorpholinyl;

[0040] halogen—represents fluorine, chlorine, bromine and iodine;

[0041] heteroaryl—represents a cyclic organic group having at least oneO, S and/or N atom interrupting a carbocyclic ring structure and havinga sufficient number of delocalized pi electrons to provide aromaticcharacter, with the aromatic heterocyclic group having from 2 to 14,preferably 4 or 5 carbon atoms, e.g., 2-, 3- or 4-pyridyl, 2- or3-furyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 2- or 4-imidazolyl, 2-,4- or 5-pyrimidinyl, 2-pyrazinyl, or 3- or 4-pyridazinyl, etc. Preferredheteroaryl groups are 2-, 3- and 4-pyridyl; such heteroaryl groups mayalso be optionally substituted.

[0042] The term “pharmaceutically acceptable salt” is a non-toxicorganic or inorganic acid addition salt of the base compoundsrepresented by Formulas I and II.

[0043] Included within the scope of the present invention are theindividual stercoisomers, diastereomers and geometric isomers of formula(I) and (II), and enantiomers thereof. The term “stereoisomers” is ageneral term for all isomers of individual molecules that differ only inthe orientation of their atoms in space. It includes geometric(cis/trans) isomers, and isomers of compounds with more than one chiralcenter that are not mirror images of one another (diastereomers). Theterm “enantiomer” or “enantiomeric” refers to a molecule that isnonsuperimposable on its mirror image and hence optically active whereinthe enantiomer rotates the plane of polarized light in one direction andits mirror image rotates the plane of polarized light in the oppositedirection. The term “racemic mixture” or “racemic modification” refersto a mixture of equal parts of enantiomers and which is opticallyinactive. As used herein the prefixes “(+)” and “(−)” are employed todesignate the sign of rotation of the plane of polarized light by thecompound, with (+) meaning the compound is dextrorotatory and (−)meaning the compound is levorotatory. For amino-acids, the designationsL/D, or R/S can be used as described in IUPAC-IUB Joint Commission onBiochemical Nomenclature, Eur. J Biochem. 138, 9-37 (1984).

[0044] A further feature of the invention is pharmaceutical compositionscontaining as active ingredient a compound of Formula I (or its salt,solvate or isomers) or Formula II (or its salt, solvate or isomers)together with a pharmaceutically acceptable carrier or excipient.

[0045] The invention also provides methods for administering to apatient suffering from one or more of the aforesaid diseases atherapeutically effective inhibitory amount of a compound of Formula Ior Formula II, or pharmaceutical compositions comprising a compound ofFormula I or Formula II.

DETAILED DESCRIPTION OF THE INVENTION

[0046] In one embodiment, the present invention provides novel compoundsof Formula I or Formula II shown above, where the various symbols are asdefined. Representative amide compounds of the invention which exhibitexcellent Src kinase inhibitory activity belonging to Formula I arelisted below by names and structure.

NAMES AND STRUCTURAL FORMULAS

[0047] 1.N-[4-Amidinobenzoyl]-N-[3-phenoxybenzyl]-3-(4-biphenyl)-alanyl-glycyl-amide

[0048] IUPAC Name:

[0049] ALPHA-[[4-(AMINOIMINOMETHYL)BENZOYL][(3-PHENOXY-PHENYL)METHYL]AMINO]-N-(2-AMINO-2-OXOETHYL)-1,1′-BIPHENYL-4-PROPANAMIDE

[0050] Structure:

[0051] 2. N-[3-Amidinobenzoyl]-N-[3-(4-tert-butylphenoxy)benzyl]-cyclohexylalanyl-glycyl-amide

[0052] IUPAC Name:

[0053]3-(AMINOIMINOMETHYL)-N-[1-[[(2-AMINO-2-OXOETHYL)AMINO]CARBONYL]-2-CYCLOHEXYLETHYL]-N-[[3-[4-(1,1-DIMETHYLETHYL)PHENOXY]PHENYL]METHYL]BENZAMIDE

[0054] Structure:

[0055] 3. N-[3-Amidinobenzoyl]-N-[3-(4-tert-butylphenoxy)benzyl]-4-aminophenylalanyl-glycyl-amide

[0056] IUPAC Name:

[0057]4-AMINO-ALPHA-[[3-(AMINOIMINOMETHYL)BENZOYL][[3-[4-(1,1-DIMETHYLETHYL)PHENOXY]PHENYL]METHYL]AMINO]-N-(2-AMINO-2-OXOETHYL)BENZENEPROPANAMIDE

[0058] Structure:

[0059] 4. N-[3-Amidinobenzoyl]-N-[3-(4-tert-butylphenoxy)benzyl]-1-naphthylalanyl-glycyl-amide

[0060] IUPAC Name:

[0061]4-AMINO-ALPHA-[[3-(AMINOIMINOMETHYL)BENZOYL][[3-[4-(1,1-DIMETHYLETHYL)PHENOXY]PHENYL]METHYL]AMINO]-N-(2-AMINO-2-OXOETHYL)-1-NAPHTHALENEPROPANAMIDE

[0062] Structure:

[0063] 5. N-[3-Amidinobenzoyl]-N-[3-(4-tert-butylphenoxy)benzyl]-arginyl-glycyl-amide

[0064] IUPAC Name

[0065] 3-(AMINOIMINOMETHYL)-N-[4-[(AMINOIMINOMETHYL)AMINO]-1-[[(2-AMINO-2-OXOETHYL)AMINO] CARBONYL] BUTYL]-N-[[3-[4-(1,1-DIMETHYLETHYL) PHENOXY] PHENYL]METHYL]BENZAMIDE

[0066] Structure:

[0067] 6. N-[4-Amidinobenzoyl]-N-[3-(4-tert-butylphenoxy)benzyl]-tryptanyl-glycyl-amide

[0068] IUPAC Name:

[0069]4-AMINO-ALPHA-[[4-(AMINOIMINOMETHYL)BENZOYL][[3-[4-(1,1-DIMETHYLETHYL)PHENOXY]PHENYL]METHYL]AMINO]-N-(2-AMINO-2-OXOETHYL)1H-INDOLE-3-PROPANAMIDE

[0070] Structure:

[0071] 7.N-[4-Amidinobenzoyl]-N-[4-biphenylmethyl]-3-(4-biphenyl)alanyl-glycyl-amide

[0072] IUPAC Name:

[0073]ALPHA-[[4-(AMINOIMINOMETHYL)BENZOYL][[[1,1′-BIPHENYL]-4-YL]METHYL]AMINO]-N-(2-AMINO-2-OXOETHYL)-1,1′BIPHENYL-4-PROPANAMIDE

[0074] Structure:

[0075] Representative urea compounds of Formula II of the inventionwhich exhibit excellent Src kinase inhibitory activity are listed belowby names and structure.

[0076] 8.4-Cyclohexyl-1-[[2-(4-phenylbutanoyl)amino]-4-[1-aminocarbonyl-2-(2-naphthyl)ethylamino]carbonylaminophenyl]piperazine

[0077] IUPAC Name:

[0078]ALPHA-[[[[4-(4-CYCLOHEXYL-1-PIPERAZINYL)-3-[(1-OXO-4-PHENYLBUTYL)AMINO]PHENYL]AMINO]CARBONYL]AMINO]-2-NAPHTHALENEPROPANAMIDE

[0079] Structure:

[0080] 9.4-Cyclohexyl-1-[[2-cinnamoylamino]-4-[1-aminocarbonyl-2-(2-naphthyl)ethylamino]carbonylaminophenyl]piperazine

[0081] IUPAC Name:

[0082]ALPHA-[[[[4-(4-CYCLOHEXYL-1-PIPERAZINYL)-3-[(1-OXO-3-PHENYL-2-PROPENYL)AMINO]PHENYL]AMINO]CARBONYL] AMINO]-2-NAPHTHALENEPROPANAMIDE

[0083] Structure:

[0084] 10. Common Name:

[0085]4-Cyclohexyl-1-[[2-cinnamoylamino]-4-[(1-aminocarbonyl-3-phenyl)propylamino]carbonylaminophenyl]piperazine

[0086] IUPAC Name:

[0087]ALPHA-[[[[4-(4-CYCLOHEXYL-1-PIPERAZINYL)-3-[(1-OXO-3-PHENYL-2-PROPENYL)AMINO]PHENYL]AMINO]CARBONYL] AMINO]BENZENEBUTANAMIDE

[0088] Structure:

[0089] 11.4-Cyclohexyl-1-[[2-(4-phenylbutanoyl)amino]-4-[(1-aminocarbonyl-3-phenyl)propylamino]carbonylaminophenyl]piperazine

[0090] IUPAC Name

[0091]ALPHA-[[[[4-(4-CYCLOHEXYL-1-PIPERAZINYL)-3-[(1-OXO-4-PHENYLBUTL)AMINO]PHENYL]AMINO]CARBONYL]AMINO]BENZENEBUTANAMIDE

[0092] Structure:

[0093] 12.4-Cyclohexyl-1-[[2-cinnamoylamino]-4-[(1-aminocarbonyl-2-cyclohexylethylamino)carbonylaminophenyl]piperazine

[0094] IUPAC Name:

[0095]2-[ALPHA-[[[[4-(4-CYCLOHEXYL-1-PIPERAZINYL)-3-[(1-OXO-3-PHENYL-2-PROPENYL)AMINO]PHENYL]AMINO] CARBONYL]AMINO]]3-(CYCLOHEXYL)PROPANAMIDE

[0096] Structure:

[0097] 13. 4-(Piperidin-4-yl)carbonyl-1-[[2-(4-phenylbutanoyl)amino]-4-[1-aminocarbonyl-2-(2-naphthyl)ethylamino]-carbonylaminophenyl]homopiperazine

[0098] IUPAC Name:

[0099]2-[ALPHA-[[[[4-[HEXAHYDRO-4-(4-PIPERIDINYLCARBONYL)-1H-1,4-DIAZEPIN-1-YL]-3-[(1-OXO-5-PHENYLPENTYL)AMINO] PHENYL] AMINO]CARBONYL]AMINO]]-3-[NAPHTH-2-YL]PROPANAMIDE

[0100] Structure:

[0101] 14. 4-(Piperidin-4-yl)carbonyl-1-[[2-(2-benzofuranoyl)amino]-2-(2-naphthyl)ethylamino]carbonylaminophenyl] homopiperazine

[0102] IUPAC Name:

[0103] 2-[ALPHA-[[[[4-[HEXAHYDRO-4-(4-PIPERIDINYLCARBONYL)-1H-1,4-DIAZEPIN-1-YL]-3-[(1-OXO-1-BENZOFURAN-2-YL) AMINO] PHENYL]AMINO]CARBONYL]AMINO]]-3-(NAPHTH-2-YL)-PROPANAMIDE

[0104] Structure:

[0105] 15. 4-(Piperidin-4-yl)carbonyl-1-[[2-(2-benzofuranoyl)amino]-4-[1-aminocarbonyl-2-cyclohexylethylamino] carbonylaminophenyl]homopiperazine

[0106] IUPAC Name:

[0107] 2-[ALPHA-[[[[4-[HEXAHYDRO-4-(4-PIPERIDINYLCARBONYL)-1H-1,4-DIAZEPIN-1-YL]-3-[(1-OXO-1-BENZOFURAN-2-YL) AMINO] PHENYL]AMINO]CARBONYL]AMINO]]-3-CYCLOHEXYL-PROPANAMIDE

[0108] Structure:

[0109] 16. 4-(Piperidin-4-yl)carbonyl-1-[2-[(2-benzofuranoyl)amino]-4-[[(4-aminocarbonyl)cyclohexylmethylamino]carbonylaminophenyl]homopiperazine

[0110] IUPAC Name:

[0111]4-[ALPHA-[4-[[[[[4-[HEXAHYDRO-4-(4-PIPERIDINYL-CARBONYL)-1H-1,4-DIAZEPIN-1-YL]-3-[(1-OXO-1-BENZOFURAN-2-YL)AMINO] PHENYL] AMINO]CARBONYL] AMINO]METHYL]]-CYCLOHEX-1-YLFORMAMIDE

[0112] Structure:

[0113] 17. 4-(Methylaminomethyl)carbonyl-1-[2-[(2-benzo-furanoyl)amino]-4-[[(4-aminocarbonyl)cyclohexylmethylamino]carbonylaminophenyl]homopiperazine

[0114] IUAC Name:

[0115] 4-[ALPHA-[4-[[[[[4-[HEXAHYDRO-4-(4-[[[METHYL]AMINO]METHYL]CARBONYL)-1H-1,4-DIAZEPIN-1-YL]-3-[(1-OXO-1-BENZOFURAN-2-YL)AMINO] PHENYL] AMINO]CARBONYL] AMINO]METHYL]]CYCLOHEX-1-YLFORMAMIDE

[0116] Structure:

[0117] 18.4-(Pyrrolidin-2-yl)carbonyl-1-[2-[(2-benzo-furanoyl)amino]-4-[[(4-aminocarbonyl)cyclohexyl-methyl-amino]carbonylamino]phenyl]homopiperazine

[0118] IUPAC Name:

[0119]4-[ALPHA-[[[[4-[HEXAHYDRO-4-(2-PYRROLIDINYL-CARBONYL)-1H-1,4-DIAZEPIN-1-YL]-3-[(1-OXO-1-BENZOFURAN-2-YL)AMINO] PHENYL] AMINO]CARBONYL] AMINO]METHYL]]-CYCLOHEX-1-YLFORMAMIDE

[0120] Structure:

[0121] 19.4-(Piperidin-1-yl)-1-[2-[(2-benzofuranoyl)amino]-4-[[(4-aminocarbonyl)cyclohexylmethylamino]carbonylaminophenyl]piperidine

[0122] UPAC Name:

[0123]4-[ALPHA-[4-[[[[[4-[4-(PIPERIDIN-1-YL)-1-PIPERIDINYL]-3-[(1-OXO-1-BENZOFURAN-2-YL)AMINO] PHENYL] AMINO]CARBONYL]AMINO]METHYL]]-CYCLOHEX-1-YLFORMAMIDE

[0124] Structure:

[0125] 20. 4-(Piperidin-4-yl)carbonyl-1-[[2-(4-phenylbutanoyl)amino]-4-[1-aminocarbonyl-2-cyclohexylethylamino]carbonylaminophenyl]homopiperazine

[0126] IUPAC Name:

[0127]N-[5-[[[[1-(CARBOXY)-1-(CYCLOHEXYL-METHYL)]AMINO]-CARBONYL]AMINO]-2-[HEXAHYDRO-4-(4-PIPERIDINYL-CARBONYL)-1H-1,4-DIAZEPIN-1-YL]PHENYL]BENZENE-BUTANAMIDE

[0128] Structure:

[0129] 21. 4-(Piperidin-4-yl)carbonyl-1-[[2-(4-phenylbutanoyl)amino]-4-[(1-aminocarbonyl-2-(naphth-2-yl))ethylamino]-carbonylaminophenyl]homopiperazine

[0130] IUPAC Name:

[0131]2-[ALPHA-[[[[4-[HEXAHYDRO-4-(4-PIPERIDINYLCARBONYL)-1H-1,4-DIAZEPIN-1-YL]-3-[(1-OXO-4-PHENYL-BUTYL)AMINO] PHENYL] AMINO]CARBONYL]AMINO]]-3-(NAPHTH-2-YL)-PROPANAMIDE

[0132] Structure:

[0133] Representative sulfonamide compounds of the invention whichexhibit excellent Src kinase inhibitory activity of the Formula II arelisted by names and structure below.

[0134] 22.N-(1-Aminocarbonyl-2-methylpropyl)-2-[(4-phenylmethyl)piperidin-1-yl]-5-[(2-pyrrolidinocarbonyl)amino]phenylsulfonamide

[0135] IUPAC Name:

[0136]ALPHA-2-[[[[2-(4-BENZYL)-1-PIPERIDINYL]-5-[(PYRROLIDIN-2-YL)CARBONYLAMINO]PHENYL]SULFONYL]AMINO]-3-METHYLBUTANAMIDE

[0137] Structure:

[0138] 23.N-(1-Aminocarbonyl-2-methylpropyl)-2-[(4-phenylmethyl)piperidin-1-yl]-5-[(2-piperdino-carbonyl)amino]phenylsulfonamide

[0139] IUPAC Name:

[0140]ALPHA-2-[[[[2-(4-BENZYL)-1-PIPERIDINYL]-5-[(PIPERIDIN-4-YL)CARBONYLAMINO]PHENYL]SULFONYL] AMINO]-3-METHYLBUTANAMIDE

[0141] Structure:

[0142] 24.1-[2-[N-(2-Aminocarbonyl-3-methylbutyl)sulfonamido]-5-[2-cinnamoylamino]]phenyl-4-cyclohexylpiperazine

[0143] IUPAC Name:

[0144]ALPHA-2-[[[2-(4-CYCLOHEXYL-1-PIPERAZINYL)-5-[(1-OXO-3-PHENYL-2-PROPENYL)CARBONYLAMINO]PHENYL]SULFONYL]AMINO]-3-METHYLBUTANAMIDE

[0145] Structure:

[0146] 25.N-[[(4-Aminocarbonyl)cyclohexylmethyl]amino]-[2-[(4-phenylmethyl)piperidin-1-yl]-5-[(2-pyrrolidino-carbonyl)amino]phenyl]sulfonamide

[0147] IUPAC Name:

[0148]4-[2-[[[[[2-[(4-BENZYL)-1-PIPERIDINYL]-5-[(PYRROLIDIN-2-YL)CARBONYLAMINO]PHENYL]SULFONYL]AMINO]METHYL]]-CYCLOHEX-1-YLFORMAMIDE

[0149] Structure:

[0150] The compounds of the invention may form pharmaceuticallyacceptable salts with organic and inorganic acids. Examples of suitableacids for such salt formation are hydrochloric, sulfuric, phosphoric,acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic,ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic,cinnamic, salicyclic, 2-phenoxybenzoic, p-toluensulfonic acid, andsulfonic acids such as methane sulfonic acid and 2-hyroxyethane sulfonicacid and other mineral and carboxylic acids well known to those skilledin the art and acid metal salts such as sodium monohydrogenorthophosphate, and potassium hydrogen sulfate. Such salts can exist ineither a hydrated or substantially anhydrous form. The salts areprepared by contacting the free base form with a sufficient amount ofthe desired acid to produce a salt in the conventional manner. The freebase forms may be regenerated by treating the salt with a suitabledilute aqueous base solution such as dilute aqueous sodium hydroxide,potassium carbonate, ammonia and sodium bicarbonate. The free base formsdiffer from their corresponding salt forms somewhat in certain physicalproperties, such as solubility in polar solvents, but the salts areotherwise equivalent to their corresponding free base forms for purposesof this invention.

[0151] Depending upon the substituents on the inventive compounds, onemay be able to form salts with bases too. Thus, for example, if thereare carboxylic acid substituents in the molecule (e.g., compound 21 inthe list above), salts may be formed with inorganic as well as organicbases such as, for example, NaOH, KOH, NH₄OH, tetraalkylammoniumhydroxide, and the like.

[0152] As stated earlier, the invention includes tautomers, enantiomersand other stereolsomers of the compounds also. Such variations arecontemplated to be within the scope of the invention.

[0153] Another embodiment of the invention discloses a method of makingthe substituted carboxamides, ureas and sulfonamides disclosed above.The compounds may be prepared by several processes known in the art ofsynthetic organic chemistry. One useful method to prepare compounds ofFormula I is schematically illustrated below in connection with thecompound numbered 7 above. In general, this procedure is referred to asScheme A herein and involves: (a) bonding an amino acid to a suitablyfunctionalized polymer support; (b) coupling another suitablysubstituted amino acid thereto; (c) reacting the coupled structure withan aldehyde to form a Schiff base, which is then (d) reduced to thecorresponding amine; which, in turn, is converted to an amide by way ofreaction with an acid chloride for example, which product may be (e)converted to the thioamide; which, in turn, is (f) methylated and (g)converted to the amidino group. The product is then cleared from thesolid phase support as will be further appreciated from the followingdiscussion.

[0154] Scheme A is specifically illustrated with respect toN-[4-Amidinobenzoyl]-N-[4-biphenylmethyl]-3-(4-biphenyl)alanyl-glycyl-amide:

[0155] In Scheme A, all substituents, unless otherwise indicated, are aspreviously defined. The reagents and starting materials are readilyavailable to one of ordinary skill in the art or may be prepared byconventional methods. The starting material (1) in Scheme A is an aminofunctionalized solid phase material, which for the purposes of synthesiswas modified with linker molecule (formula III), which enables theproduct of the synthesis to be cleaved from the solid support (resin).Example of such linker is the Rink linker(p-[(R,S)-α-(9H-fluoren-9-yl)methoxyfonnamido]-2,4-dimethoxybenzyl]-phenoxyaceticacid (Bematowicz et al., Tetrahedron Lett. 30, 4645 (1989)).Commercially available resins with the desired linker already attachedcan be used as well.

[0156] The Rink linker attachment to a suitable solid phase is carriedout by reacting an amino functionalized solid support with acid moietyof the linker molecule by standard peptide synthesis techniques wellknown in the art to provide an amide linkage, as shown in Example 1.Such reaction can be carried out using standard coupling procedures suchas, for example, as described in Stewart and Young, Solid Phase PeptideSynthesis, 2^(nd) ed., Pierce Chemical Co., Rockford, Ill. (1984);Gross, Meienhofer, Udenfriend, Ed., The Peptides: Analysis, Synthesis,Biology, Vol. 1, 2, 3, 5 and 9, Academic Press, New York, 1980-1987;Bodanszky, Peptide Chemistry: A Practical Textbook, Springer-Verlag, NewYork (1988); and Bodanszky, et al. The Practice of Peptide SynthesisSpringer-Verlag, New York (1984), the disclosures of which are herebyincorporated by reference. If a coupling reagent (activator) is needed,suitable coupling reagent may be selected from dicyclohexylcarbodiimide(DCC), diisopropylcarbodiimide (DIC),1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquioline (EEDQ),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI),n-propanephosphonic anhydride (PPA),N,N-bis(2-oxo-3-oxazolidinyl)amidophosphoryl chloride (BOP-CI),diphenylphosphoryl azide, (DPPA), Castro's reagent (BOP),2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium salts (HBTU),2,5-diphenyl-2,3-dihydro-3-oxo-4-hydroxythiophene dioxide (Steglich'sreagent' HOTDO) and 1,1′carbonyldiimidazole (CDI). The coupling reagentmay be used alone or in combination with additives such as4-dimethylaminopyridine (DMAP), N-hydroxybenzotriazole (HOBt),N-hydroxybenzotriazine (HOOBt), N-hydroxysuccinimide) HOSu) or2-hydroxypyridine. The coupling reactions can be performed in eithersolution (liquid phase) or solid phase.

[0157] As used herein, the term “solid phase support” is not limited toa specific type of support. A large number of supports are available andare known to one of ordinary skill in the art. Solid phase supportsinclude silica gels, resins, derivatized plastic films, glass beads,cotton, plastic beads, alumina gels, polysaccharides and the like. Asuitable solid phase support may be selected on the basis of desired enduse and suitability for various synthetic protocols. For example, forpeptide synthesis, solid phase support may refer to resins such asp-methylbenzhydrylamine (pMBHA) resin (from Peptides International,Louisville, Ky.), polystyrene (e.g., PAM-resin available from BachemInc.(Torance, Calif., USA), poly (dimethylacrylamide)-grafted styreneco-divinyl-benzene (e.g., POLYHIPE® resin, available from Aminotech,Nepean, Ontario, Canada), polyamide resin (e.g. Spar-resin, availablefrom AdvancedChemtech, Louisville, Ky., USA), polystyrene resin graftedwith polyethylene glycol (available from TentaGel®, Rapp Polymere,Tubingen, Germany) polydimethylacrylamide resin (available fromMilligen/Biosearch, Burlington, Mass., USA), or Sepharose (availablefrom Pharmacia Corporation, Stockholm, Sweden).

[0158] The amino acid moiety may carry protecting groups prior to thecoupling reaction. Examples of suitable protecting groups include thefollowing: (1) acyl types such as formyl, trifluoracetyl, phthalyl, andp-toluenesulfonyl; (2) aromatic carbamate types such asbenzyloxycarbonyl (Cbz or Z) and substituted benzyloxy-carbonyls,1-(p-biphenyl)-1-methylethoxy-carbonyl, and9-fluorenylmethyloxy-carbonyl (Fmoc); (3) aliphatic carbamate types suchas tertbutyloxycarbonyl (Boc), ethoxycarbonyl,diisopropyl-methoxycarbonyl, and allyloxycarbonyl; (4) cyclic alkylcarbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl;(5) alkyl types such as triphenyl-methyl and benzyl; (6) trialkysilanesuch as trimethyl-silane; and (7) thiol containing types such asphenylthio-carbonyl and dithiasuccinoyl. The preferred protecting groupis either Boc or Fmoc.

[0159] If certain functional groups or side chains on the amino acidmoiety need to be protected during the coupling reaction to avoidformation of undesired bond, suitable protecting groups that can be usedfor that purpose are listed in Greene, Protective Groups in OrganicChemistry, John Wiley & Sons, New York (1981) and The Peptides:Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981),the disclosures of which are hereby incorporated by reference. Thoseskilled in the art will appreciate the fact that the selection and useof appropriate protecting groups depend upon the overall structure ofthe amino acid compound and the presence of any other protecting groupson that compound. The selection of such a protecting group may beespecially important if it should not be removed during the deprotectionof the other protecting group.

[0160] Suitable amino acids for the coupling reaction are listed inTable 1 along with the symbol for each amino acid. TABLE 1 AMINO ACIDSYMBOL Alanine Ala or A Arginine Arg or R Asparagines Asn or N Asparticacid Asp or D Cysteine Cys or C Glutamine Gin or Q Glutamic acid Glu orE Glycine Gly or G Histidine His or H Isoleucine Ile or I Leucine Leu orL Lysine Lys or K Methionine Met or M Phenylalanine Phe or F Proline Proor P Serine Ser or S Threonine Thr or T Tryptophan Trp or W Tyrosine Tyror Y Valine Val or V

[0161] More specifically, a solid phase support such as, for example, adeprotected RAM-PS resin is typically treated with 3 equivalents of theamino acid moiety and 3 equivalents of 1-hydroxybenzotriazole in asuitable organic solvent, such a N,N-dimethylformamide. Then 3equivalents of diisopropylcarbodiimide are added and the mixture shakenfor about 30 minutes to five hours. The amide that is produced can beisolated and purified by well known techniques or the crude material canbe carried on to deprotection as it is.

[0162] The amide produced in the above-noted step is deprotected underconditions which do not cleave the solid phase support from the growingcompound. Such conditions are well known in the art. Thus, when the Bocprotecting group is used, the methods of choice are trifluoroacetic acideither neat or in dichloromethane, or HCI in dioxane or ethyl acetate.The resulting ammonium salt is then neutralized either prior to thecoupling or in situ with basic solutions such as aqueous buffers, ortertiary amines in dichloromethane or dimethylformamide. When the Fmocprotecting group is used, the reagents of choice are piperidine orsubstituted piperidine in dimethylformamide, but any secondary amine oraqueous basic solutions can be used. The deprotection is carried outgenerally at a temperature of between about 0° C. and about roomtemperature. For example, the above-noted crude amide may be treatedwith 30% piperidine in N, N-dimethylformamide for about 20 minutes toabout one hour, following which the reaction mixture is filtered toprovide the deprotected compound.

[0163] To the deprotected compound on solid phase, a suitablyamino-protected compound having free carboxylic function (for example,Fmoc-protected biphenylalanine in Scheme A) to form the solid phaselinked product. For example, 1 equivalents of the deprotected compoundmay be combined with 3 equivalents of Fmoc-Biphenylalanine and 3equivalents of 1-hydroxybenzo-triazole and a suitable activator (forexample 3 equivalents of DIC) in a suitable organic solvent, such asN,N-dimethylformamide. The formed biphenylalanine linked compound iscleaved of the Fmoc group and then reacted with a suitable aldehyde,such as, for example, 4-phenylbenzaldehyde, to yield the correspondingSchiff base. The Schiff base is then reduced, for example, with sodiumborohydride, sodium cyanoborohydride and the like, to form thecorresponding amine which is then converted to the amide by reactingwith, for example, an acid chloride, in this case, 4-cyanobenzoylchloride. The amide may be converted to the thioamide which ismethylated and then converted to the amidino group. The product is thencleaved of the solid phase support to yield compound 7.

[0164] The compounds of Formula II where X is an urea may be prepared asdescribed in Scheme B:

[0165] Scheme B may be explained with the synthesis of a compound ofFormula II where R₁ is 2-naphthylmethyl, R₂ is cyclohexylpiperazinyl, R₃is 3-phenylpropyl, X is —NH—CO—, Y is CONH2 and n is 1. That compound iscompound 8 identified above, 4-Cyclohexyl-1-[[2-(4-phenylbutanoyl)amino]-4-[1-aminocarbonyl-2-(2-naphthyl)ethylamino]carbonylaminophenyl]piperazine

[0166] Thus, a solid phase support is coupled with a protected aminoacid, in this case, Fmoc-2-naphthylalanine in the presence of anactivator such as, for example, 1-hydroxybenzotriazole and DIC. It isthen deprotected and then reacted with 4-fluoro-3-nitrophenylisocyanateand the fluorinated product is then reacted with 4-cyclohexylpiperazineto introduce the R₂ group. The nitro group is then reduced with stannouschloride to the amine which is converted to the 4-phenylbutyl amide byreacting with 4-phenylbutyric acid by activation with HOAt and DIC.Cleaving of the solid support yields the desired compound 8. Similarly,one synthesizes the other urea compounds by appropriate selection of theR₁, R₂ and R₃ substituted reactants.

[0167] Synthesis of a compound of Formula II where X is sulfonamide issimilar to that shown in Scheme B except that in the step introducingthe fluoronitrophenyl-isocyanate, the appropriate fluoronitrobenzenesulfonyl chloride is used. Thus, replacing the isocyanate in the abovedescription with 2-fluoro-5-nitrobenzene sulfonyl chloride would yieldthe desired sulfonamide compound.

[0168] Isolation of the compound at various stages of the reactionscheme may be achieved after cleavage from solid support by standardtechniques such as, for example, filtration, evaporation of solvent andthe like. Purification of the product, intermediate and the like, mayalso be performed by standard techniques such as recrystallization,distillation, sublimation, chromatography, conversion to a suitablederivative which may be recrystallized and converted back to thestarting compound, and the like. Such techniques are well known to thoseskilled in the art.

[0169] The thus prepared compounds may be analyzed for their compositionand purity as well as characterized by standard analytical techniquessuch as, for example, elemental analysis, NMR, mass spectroscopy, and IRspectra.

[0170] In another embodiment, this invention provides pharmaceuticalcompositions comprising the above-described inventive compounds as anactive ingredient. The pharmaceutical compositions generallyadditionally comprise a pharmaceutically acceptable carrier diluent,excipient or carrier (collectively referred to herein as carriermaterials). Because of their therapeutic activity against osteoporosisand bone tissue loss, such pharmaceutical compositions possess utilityin treating those diseases.

[0171] In yet another embodiment, the present invention disclosesmethods for preparing pharmaceutical compositions comprising thecompounds of Formula I or Formula II as an active ingredient. In thepharmaceutical compositions and methods of the present invention, theactive ingredient or ingredients will generally be administered inadmixture with suitable carrier materials suitably selected with respectto the intended form of administration, i.e. oral tablets, capsules(either solid-filled, semi-solid filled or liquid filled), powders forconstitution, oral gels, elixirs, dispersible granules, syrups,suspensions, and the like, and consistent with conventionalpharmaceutical practices. For example, for oral administration in theform of tablets or capsules, the active drug component may be combinedwith any oral non-toxic pharmaceutically acceptable inert carrier, suchas lactose, starch, sucrose, cellulose, magnesium stearate, dicalciumphosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms)and the like. Moreover, when desired or needed, suitable binders,lubricants, disintegrating agents and coloring agents may also beincorporated in the mixture. Powders and tablets may be comprised offrom about 5 to about 95 percent inventive composition. Suitable bindersinclude starch, gelatin, natural sugars, corn sweeteners, natural andsynthetic gums such as acacia, sodium alginate, carboxymethylcellulose,polyethylene glycol and waxes. Among the lubricants there may bementioned for use in these dosage forms, boric acid, sodium benzoate,sodium acetate, sodium chloride, and the like. Disintegrants includestarch, methylcellulose, guar gum and the like.

[0172] Sweetening and flavoring agents and preservatives may also beincluded where appropriate. Some of the terms noted above, namelydisintegrants, diluents, lubricants, binders and the like, are discussedin more detail below.

[0173] Additionally, the compositions of the present invention may beformulated in sustained release form to provide the rate controlledrelease of any one or more of the components or active ingredients tooptimize the therapeutic effects, i.e. antihistaminic activity and thelike. Suitable dosage forms for sustained release include layeredtablets containing layers of varying disintegration rates or controlledrelease polymeric matrices impregnated with the active components andshaped in tablet form or capsules containing such impregnated orencapsulated porous polymeric matrices.

[0174] Liquid form preparations include solutions, suspensions andemulsions. As an example may be mentioned water or water-propyleneglycol solutions for parenteral injections or addition of sweeteners andpacifiers for oral solutions, suspensions and emulsions. Liquid formpreparations may also include solutions for intranasal administration.

[0175] Aerosol preparations suitable for inhalation may includesolutions and solids in powder form, which may be in combination with apharmaceutically acceptable carrier such as inert compressed gas, e.g.nitrogen.

[0176] For preparing suppositories, a low melting wax such as a mixtureof fatty acid glycerides such as cocoa butter is first melted, and theactive ingredient is dispersed homogeneously therein by stirring orsimilar mixing. The molten homogeneous mixture is then poured intoconvenient sized molds, allowed to cool and thereby solidify.

[0177] Also included are solid form preparations which are intended tobe converted, shortly before use, to liquid form preparations for eitheroral or parenteral administration. Such liquid forms include solutions,suspensions and emulsions.

[0178] The compounds of the invention may also be deliverabletransdermally. The transdermal compositions may take the form of creams,lotions, aerosols and/or emulsions and can be included in a transdermalpatch of the matrix or reservoir type as are conventional in the art forthis purpose.

[0179] Preferably the compound is administered orally.

[0180] Preferably, the pharmaceutical preparation is in a unit dosageform. In such form, the preparation is subdivided into suitably sizedunit doses containing appropriate quantities of the active components,e.g., an effective amount to achieve the desired purpose.

[0181] The quantity of the inventive active composition in a unit doseof preparation may be generally varied or adjusted from about 1.0milligram to about 1,000 milligrams, preferably from about 1.0 to about950 milligrams, more preferably from about 1.0 to about 500 milligrams,and typically from about 1 to about 250 milligrams, according to theparticular application. The actual dosage employed may be varieddepending upon the patient's age, sex, weight and severity of thecondition being treated. Such techniques are well known to those skilledin the art.

[0182] Generally, the human oral dosage form containing the activeingredients can be administered 1 or 2 times per day. The amount andfrequency of the administration will be regulated according to thejudgment of the attending clinician. A generally recommended dailydosage regimen for oral administration may range from about 1.0milligram to about 1,000 milligrams per day, in single or divided doses.

[0183] The term “capsule” refers to a special container or enclosuremade of methylcellulose, polyvinyl alcohols, or denatured gelatins orstarch for holding or containing compositions comprising the activeingredients. Hard shell capsules are typically made of blends ofrelatively high gel strength bone and pork skin gelatins. The capsuleitself may contain small amounts of dyes, opaquing agents, plasticizersand preservatives.

[0184] The term “tablet” refers to a compressed or molded solid dosageform containing the active ingredients with suitable diluents. Thetablet can be prepared by compression of mixtures or granulationsobtained by wet granulation, dry granulation or by compaction.

[0185] The term “oral gel” refers to the active ingredients dispersed orsolubilized in a hydrophilic semi-solid matrix.

[0186] The term “powders for constitution” refers to powder blendscontaining the active ingredients and suitable diluents which can besuspended in water or juices.

[0187] The term “diluent” refers to substances that usually make up themajor portion of the composition or dosage form. Suitable diluentsinclude sugars such as lactose, sucrose, mannitol and sorbitol; starchesderived from wheat, corn, rice and potato; and celluloses such asmicrocrystalline cellulose. The amount of diluent in the composition canrange from about 10 to about 90% by weight of the total composition,preferably from about 25 to about 75%, more preferably from about 30 toabout 60% by weight, even more preferably from about 12 to about 60%.

[0188] The term “disintegrant” refers to materials added to thecomposition to help it break apart (disintegrate) and release themedicaments. Suitable disintegrants include starches; “cold watersoluble” modified starches such as sodium carboxymethyl starch; naturaland synthetic gums such as locust bean, karaya, guar, tragacanth andagar; cellulose derivatives such as methylcellulose and sodiumcarboxymethylcellulose; microcrystalline celluloses and cross-linkedmicrocrystalline celluloses such as sodium croscarmellose; alginatessuch as alginic acid and sodium alginate; clays such as bentonites; andeffervescent mixtures. The amount of disintegrant in the composition canrange from about 2 to about 15% by weight of the composition, morepreferably from about 4 to about 10% by weight.

[0189] The term “binder” refers to substances that bind or “glue”powders together and make them cohesive by forming granules, thusserving as the “adhesive” in the formulation. Binders add cohesivestrength already available in the diluent or bulking agent. Suitablebinders include sugars such as sucrose; starches derived from wheat,corn rice and potato; natural gums such as acacia, gelatin andtragacanth; derivatives of seaweed such as alginic acid, sodium alginateand ammonium calcium alginate; cellulosic materials such asmethylcellulose and sodium carboxymethylcellulose andhydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics suchas magnesium aluminum silicate. The amount of binder in the compositioncan range from about 2 to about 20% by weight of the composition, morepreferably from about 3 to about 10% by weight, even more preferablyfrom about 3 to about 6% by weight.

[0190] The term “lubricant” refers to a substance added to the dosageform to enable the tablet, granules, etc. after it has been compressed,to release from the mold or die by reducing friction or wear. Suitablelubricants include metallic stearates such as magnesium stearate,calcium stearate or potassium stearate; stearic acid; high melting pointwaxes; and water soluble lubricants such as sodium chloride, sodiumbenzoate, sodium acetate, sodium oleate, polyethylene glycols andd'l-leucine. Lubricants are usually added at the very last step beforecompression, since they must be present on the surfaces of the granulesand in between them and the parts of the tablet press. The amount oflubricant in the composition can range from about 0.2 to about 5% byweight of the composition, preferably from about 0.5 to about 2%, morepreferably from about 0.3 to about 1.5% by weight.

[0191] The term “glident” materials that prevent caking and improve theflow characteristics of granulations, so that flow is smooth anduniform. Suitable glidents include silicon dioxide and talc. The amountof glident in the composition can range from about 0.1% to about 5% byweight of the total composition, preferably from about 0.5 to about 2%by weight.

[0192] The term “coloring agent” refers to excipients that providecoloration to the composition or the dosage form. Such excipients caninclude food grade dyes and food grade dyes adsorbed onto a suitableadsorbent such as clay or aluminum oxide. The amount of the coloringagent can vary from about 0.1 to about 5% by weight of the composition,preferably from about 0.1 to about 1%.

[0193] The term “bioavailability” refers to the rate and extent to whichthe active drug ingredient or therapeutic moiety is absorbed into thesystemic circulation from an administered dosage form as compared to astandard or control.

[0194] Conventional methods for preparing tablets are known. Suchmethods include dry methods such as direct compression and compressionof granulation produced by compaction, or wet methods or other specialprocedures. Conventional methods for making other forms foradministration such as, for example, capsules, suppositories and thelike are also well known.

[0195] Another embodiment of the invention discloses use of thepharmaceutical compositions disclosed above for treatment of diseasessuch as, for example, osteoporosis and bone tissue loss.

[0196] It will be apparent to those skilled in the art that manymodifications, variations and alterations to the present disclosure,both to materials and methods, may be practiced. Such modifications,variations and alterations are intended to be within the spirit andscope of the present invention.

[0197] The following examples are being provided to further illustratethe present invention. They are for illustrative purposes only; thescope of the invention is not to be considered limited in any waythereby.

EXAMPLES

[0198] Unless otherwise stated, the following abbreviations have thestated meanings in the Examples below:

[0199] DCC=dicyclohexylcarbodiimide

[0200] NaBH(OAc)₃=sodium triacetoxyborohydride

[0201] FMOC=9-fluorenylmethyloxycarbonyl

[0202] DCE=1,2-dichloroethane

[0203] DIEA=diisopropylethylamine

[0204] Cha=cyclohexylalanine

[0205] Na1(1)=1-naphthylalanine

[0206] TEOF=triethylorthoformate

[0207] TIPS=triisopropylsilane

[0208] Na1(1)=1-naphthylalanine

[0209] Bip=4-biphenylalanine

[0210] Boc=tert.butyloxycarbonyl

[0211] Pip=piperidine

[0212] HOAc=acetic acid

[0213] TFA=trifluoroacetic acid

[0214] Py=pyridine

[0215] DIC=diisopropylcarbodiimide

[0216] MeOH=methanol

[0217] NaBH₄=sodium borohydride

[0218] NaBH₃CN=sodium cyanoborohydride

[0219] p-TsOH=p-toluenesulfonic acid

[0220] DMF: N,N-Dimethylformamide

[0221] THF: Tetrahydrofuran

[0222] DMSO: Dimethyl sulfoxide

[0223] DCM: Dichloromethane which can also be referred to as methylenechloride

[0224] LAH: Lithium aluminum hydride

[0225] HOAt: 1-Hydroxy-7-azabenzotriazole

[0226] HOBt: 1-Hydroxybenzotriazole

[0227] HRMS=High Resolution Mass Spectrometry

[0228] HPLC=High Performance Liquid Chromatography

[0229] NMR=nuclear magnetic resonance

[0230] LRMS=Low Resolution Mass Spectrometry

[0231] nM=nanomolar

[0232] Additionally, “kg” refers to kilograms; “g” refers to grams; “mg”refers to milligrams; “μg” refers to micrograms; “m²/g” refers to squaremeters per gram and is used as a measurement of particle surface area;“mmol” refers to millimoles; “L” refers to liters; “mL” refers tomilliliters; “μL” refers to microliters; “cm” refers to centimeters; “M”refers to molar' “mM” refers to millimolar; “μM” refers to micromolar;“nM” refers to nanomolar; “N” refers to normal; “ppm” refers to partsper million; “δ” refers to parts per million down field fromtetramethylsilane; “° C.” refers to degrees Celsius; “° F.” refers todegrees Fahrenheit; “mm Hg” refers to millimeters of mercury; “kPa”refers to kilopascals; “psi” refers to pounds per square inch; “rpm”refers to revolutions per minute; “bp” refers to boiling point; “mp”refers to melting point; “dec” refers to decomposition; “h” refers tohours; “min” refers to minutes; “sec” refers to seconds' “R_(f)” refersto retention factor; and “R_(t)” refers to retention time.

[0233] Examples 1-7 pertain to synthesis of compounds of Formula I.

[0234] General Synthesis Procedures

[0235] Starting materials used in the synthesis were obtained fromchemical vendors such as Aldrich, Sigma, Fluka, Nova Biochem andAdvanced Chemtech. During the synthesis, the functional groups of theamino acid derivatives used were protected by blocking groups to preventside reaction during the coupling steps. Examples of suitable protectinggroups and their use are described in The Peptides, supra, 1981, and invol. 9, Udenfriend and Meienhofer (eds.), 1987, which is incorporatedherein by reference.

[0236] General solid-phase peptide synthesis was used to produce thecompounds of the invention. Such methods are described, for example, bySteward and Young, Solid Phase Peptide Synthesis (Freeman & Co., SanFrancisco, 1969), which is incorporated herein by reference.

[0237] Unless indicated otherwise, peptides were synthesized onRAM™-Polystyrene Resin (Rapp Polymere, Tübingen, Germany). As analternative to this, acid sensitive linkerp-[(R,S)-α-[1-(9H-fluoren-9-yl)methoxyformamido]-2,4-dimethoxybenzyl]phenoxyaceticacid (Knorr Linker, Bernatowicz et. al, Tetr. Lett. 30 (1989) 4645,which is incorporated herein by reference) can be coupled to any aminofunctionalized the solid support or the desired compounds can besynthesized on polystyrene resin cross-linked with 1% divinylbenzenemodified with an acid sensitive linker (Rink resin) (Rink, Tetr. Lett.28 (1987) 3787; Sieber, Tetr. Lett. 28 (1987) 2107, each of which isincorporated herein by reference). Coupling was performed usingN,N′-diisopropylcarbodiimide (DIC) in the presence of an equivalentamount of HOBt. All couplings were done N,N-dimethylformamide (DMF) atroom temperature (RT). Completion of coupling was monitored by ninhydrintest. A second (double) coupling was performed where coupling in thefirst instance was incomplete.

[0238] Deprotection of the Fmoc group was accomplished using 50%piperidine in DMF for 2+15 min. The amount of Fmoc released wasdetermined from the absorbance at 302 nm of the solution afterdeprotection, volume of washes and weight of the resin used in thesynthesis.

[0239] The compound resin was at the end of the synthesis washedsuccessively with DMF and DCM and the peptide was then cleaved anddeprotected by a mixture TFA/TIPS (99/1) for 2 hours, unless specifiedotherwise. The resin was washed with DCM and the DCM wash combined withthe TFA releasate. The solution was evaporated, the product wasredissolved in a mixture of water and acetonitrile and lyophylized.

[0240] The dried compound was subjected to HPLC purification using anappropriate gradient of 0.1% TFA in water and acetonitrile (ACN). Aftercollecting the peak containing the intended synthetic product, thesolution was lyophilized and the compound was subjected to anidentification process, which included electrospray mass spectrum (MS)and/or NMR to confirm that the correct compound was synthesized.

[0241] For HPLC analysis, a sample of the product was analyzed usingBeckman HPLC system (consisting of 126 Solvent Deliver System, 166Programmable Detector Module 507e Autosampler, controlled by DataStation with Gold Nouveau software) and YMC ODS-AM 4.6×250 mm column at230 nm and flow rate 1 ml/min.

[0242] For product purification, a sample of crude lyophilized compoundwas dissolved in a mixture of 0.1% aqueous TFA containing 10% to 50%ACN. The solution of the product was usually filtered through a syringeconnected to a 0.45 μm “ACRODISC” 13 CR PTFE (Gelman Sciences; Ann ArborMich.) filter. A proper volume of filtered compound solution wasinjected into a semi-preparative C18 column (YMC ODS-A column (20×250mm), YMC, Inc., Wilmington, N.C.). The flow rate of a gradient orisocratic mixture of 0.1% TFA buffer and ACN (HPLC grade) as an eluentwas maintained using a Beckman “SYSTEM GOLD” HPLC (Beckman, System Gold,Programmable Solvent Module 126 and Programmable Detector Module 166controlled by “SYSTEM GOLD” software). Elution of the compound wasmonitored by UV detection at 230 nm. After identifying the peakcorresponding to the compound under synthesis using MS, the compound wascollected, lyophilized and biologically tested. MS was performed using aVG Platform (Fisons Instruments) instrument in ES+ mode. For NMR,typically samples were measured in DMSO-d₆ (Aldrich) using a BrukerAvance DPX 300 instrument.

Example 1N-[4-Amidinobenzoyl]-N-[3-phenoxybenzyl]-3-(4-biphenyl-alanyl-glycyl-amide

[0243]

[0244] Following generally the procedure described above as Scheme A,polystyrene-RAM (substitution 0.74 mmol/g, 100-200 mesh, Rapp Polymere,Tubingen, Germany, 0.5 g) was washed with DMF and the Fmoc-protectinggroup cleaved by 50% solution of piperidine in DMF (twice 10 minutes, 5ml each). The resin was then washed by DMF. Fmoc-Gly-OH (3 eq) activatedwith DIC/HOBt (3 eq each) in DMF (3 ml) was coupled to the resinovernight and the completion was checked by ninhydrin test. AfterFmoc-group deprotection, the resin-bound intermediate was reacted withFmoc-4-biphenyl-alanine (3 eq, in 3 ml DMF) activated with DIC/HOBt (3eq each) overnight. Fmoc group was deprotected as described above andthe resin was washed with DMF. Resin was washed with DCM and a solutionof 3-phenoxybenzaldehyde (7 eq) in 5 ml TEOF/DCM (4:1) was added and thereaction was carried out for 6 hours, the resin was washed with DCM (3times) and the formed Schiff base was reduced with 5 ml of solutionNaBH₃CN overnight. This was prepared by mixing 1M NaBH₃CN in THF(commercially available) with DCE/MeOH/AcOH (80:18:2) in ratio 1:4.After the reduction resin was washed with MeOH, DMF, 10% DIEA in DMF,DMF and DCE. The resin-bound amine was reacted with 5 eq of4-cyanobenzoyl chloride in 5 ml DCE with 5 eq DIEA overnight. Resin wasthen washed with DCE, DMF, with mixture pyridine/Et₃N (2:1) and treatedwith 8 ml of saturated solution of H₂S in Pyridine/Et₃N (2:1). After 5hours, the solution was removed and the procedure repeated. Afterovernight standing, the resin was washed with acetone. The resultingthioamide was converted to the thioimidate by reaction with methyliodidein acetone ((4 ml of 20% solution, overnight). The resin was washed withacetone and MeOH, and a solution of 20 eq of ammonium acetate inmethanol containing 20 eq of acetic acid was added and the kept at 50°C. for 3 hours. The resin was then washed with MeOH, DMF and DCM. Theproduct was cleaved by TFA(1% TIPS). The crude product was purified bypreparative HPLC. MS analysis: calculated 625.3 (M), found 626.2 (MH)+.

Example 2 Preparation of3-amidinobenzoyl-(3-(4-tert-butylphenoxy)benzyl)-cyclohexylylalanyl-glycyl-amide

[0245]

[0246] The title compound was synthesized using Fmoc-Gly-OH,Fmoc-Cha-OH, 3-(4-tert. Butylphenoxy) benzaldehyde and 3-cyanobenzoylchloride according to procedures described in Example 1. MS analysis:calculated 611.4 (M), found 612.3 (MH)+.

Example 3 N[3-Amidinobenzoyl]-N-[3-(4-tert-butylphenoxy)benzyl]-4-aminopheylalanyl-glycyl-amide

[0247]

[0248] The tile compound was synthesized using Fmoc-Gly-OH,Fmoc-Phe(4-NH-Boc)-OH, 3-(4-tert.Butylphenoxy) benzaldehyde and3-cyanobenzoyl chloride according to procedures described in Example 1.MS analysis: calculated 620.3 (M), found 621.3 (MH)+.

Example 4 N-[3-Amidinobenzoyl]-N-[3-(4-tert-butylphenoxy)benzyl]-1-naphthylalanyl-glycyl-amide

[0249]

[0250] The title compound was synthesized using Fmoc-Gly-OH,Fmoc-Nal(1)-OH, 3-(4-tert. Butylphenoxy) benzaldehyde and 3-cyanobenzoylchloride according to procedures described in Example 1. MS analysis:calculated 655.3 (M), found 656.2 (MH)+.

Example 5 N-[3-Amidinobenzoyl]-N-[3-(4-tert-butylphenoxy)benzyl]-arginyl-glycyl-amide

[0251]

[0252] The title compound was synthesized using Fmoc-Gly-OH,Fmoc-Arg(Boc)2-OH, 3-(4-tert. Butylphenoxy) benzaldehyde and3-cyanobenzoyl chloride according to procedures described in Example 1.MS analysis: calculated 614.3 (M), found 615.2 (MH)+.

Example 64-amidinobenzoyl-(3-(4-tert-butylphenoxy)phenoxybenzyl)-tryptanyl-glycyl-amide

[0253]

[0254] The title compound was synthesized using Fmoc-Gly-OH,Fmoc-Trp(Boc)-OH, 3-(4-tert. Butylphenoxy) benzaldehyde and4-cyanobenzoyl chloride according to procedures described in Example 1.MS analysis: calculated 644.3 (M), found 645.2 (MH)+.

Example 7N-[4-Amidinobenzoyl]-N-[4-biphenylmethyll-3-(4-biphenyl)alanyl-glycyl-amide

[0255]

[0256] The title compound was synthesized using Fmoc-Gly-OH,Fmoc-Bip-OH, 4-phenylbenzaldehyde and 4-cyanobenzoyl chloride accordingto procedures described in Example 1. MS analysis: calculated 609.3 (M),found 610.2 (MH)+.

[0257] Examples 8-15 describe the synthesis of compounds of Formula IIwhere X is a urea moiety.

Example 84-Cyclohexyl-1-{[2-(4-phenylbutanoyl)amino]-4-[1-aminocarbonyl-2-(2-naphthyl)ethylamino]carbonylaminophenyl}piperazine

[0258]

[0259] Following generally the procedure described above in connectionwith Scheme B, commercial Polystyrene-RAM resin (0.74 mmol/g) (RappPolymere, Tubingen, Germany, 0.25 g) was slurried in dichloromethane,washed with DMF and treated for 30 minutes with a mixture of piperidineand DMF (1:1 v/v). The resin was washed with DMF (5×), DCM (5×) and DMF(3×) and then coupled with 0.5 mmol of Fmoc-(L)-2-naphthylalanine,1-hydroxybenzotriazole and diisopropyl-carbodiimide in 3 ml DMFovernight. The resin was washed with DMF (5×) and treated withpiperidine/DMF again for 30 minutes. After washing as described above,the coupling with 0.5 mmol of 4-fluoro-3-nitrophenylisocyanate in 2 mlDMF was carried out over night. The resin was washed with DMF (5×) andtreated with 3 ml of a 0.5 molar solution of 1-cyclohexylpiperazine inDMF for 3 hours at 60°. After washing with DMF (10×), the nitro groupwas reduced by shaking the resin with 4 ml of a molar solution of tinchloride dihydrate in DMF for 24 hours. The resin was washed with DMF(5×), MeOH (5×), DCM (5×), DMF containing 5% of diisopropylethylamine(1×) and DMF (3×). The final coupling with 1 mmol of 4-phenyl butyricacid, 1-hydroxy-7-azabenzotriazole and diisopropylcarbodiimide in 3 mlDMF was performed over night. Following extensive washing of the resinwith DMF, methanol and DCM and subsequent drying, it was cleaved with 3ml of 95% trifluoroacetic acid. The TFA solution was evaporated and theresidue was combined with the washings of the resin with methanol.Evaporation yielded the crude title compound which was purified bypreparative HPLC using the standard acetonitrile/−water+0.1% TFAgradient and a Vydac C-18 column. The pure sample had a M+1 ion at 661.3in the mass spectrum and was homogenous by HPLC with a retention time of26.95 minutes.

Example 94-Cyclohexyl-1-{[2-cinnamoylaminol-4-[1-aminocarbonyl-2-(2-naphthyl)ethylamino]carbonylaminophenyl}piperazine

[0260]

[0261] This was prepared by the method of Example 8 using trans-cinnamicacid in the final coupling step to give the title compound with M+1 ionat 645.3 and a retention time of 26.88 minutes.

Example 104-Cyclohexyl-1-1-{[2-cinnamoylaminol-4-[(1-aminocarbonyl-3-phenyl)propylamino]carbonylaminophenyl}piperazine

[0262]

[0263] This compound was prepared by the method of Example 8 usingFmoc-homophenylalanine in the initial coupling step to give the titlecompound with M+1 ion at 609.3 and retention time of 25.78 minutes.

Example 114-Cyclohexyl-1-{[2-(4-phenylbutanoyl)amino]-4-(1-aminocarbonyl-3-phenyl)propylamino]carbonylaminophenyl}piperazine

[0264]

[0265] This compound was prepared by the method of Example 8 usingFmoc-homophenylalanine in the initial coupling step to give the titlecompound with M+1 at 625.3 and a retention time of 26 minutes.

Example 124-Cyclohexyl-1-{[2-cinnamoylaminol-4-[(1-aminocarbonyl-2-cyclohexyl)ethylamino]carbonylaminophenyl}piperazine

[0266]

[0267] This compound was prepared by the method of Example 8 usingFmoc-cyclohexylalanine in the initial coupling step to give the titlecompound with M+1 ion at 601.3 and retention time of 26.72 minutes.

Example 134-(Piperidin-4-yl)carbonyl-1-{[2-(4-phenylbutanoyl)amino]-4-[1-aminocarbonyl-2-(2-naphthyl)ethylamino]carbonylaminophenyl}homopiperazine

[0268]

[0269] Following generally the procedure shown in Scheme B above,commercial Polystyrene-RAM resin (0.74 mmol/g) (Rapp Polymere, Tubingen,Germany, 0.25 g) was slurried in dichloromethane, washed with DMF andtreated for 30 minutes with a mixture of piperidine and DMF (1:1 v/v).The resin was washed with DMF (5×), DCM (5×) and DMF (3×) and thencoupled with 0.5 mmol of Fmoc-(L)-2-naphthylalanine,1-hydroxybenzotriazole and diisopropylcarbodiimide in 3 ml DMF overnight. The resin was washed with DMF (5×) and treated withpiperidine/DMF again for 30 minutes. After washing as described above,the coupling with 0.5 mmol of 4-fluoro-3-nitrophenylisocyanate in 2 mlDMF was carried out over night. The resin was washed with DMF (5×) andtreated with 3 ml of a 0.5 molar solution of homopiperazine in DMF for 2hours at 60°. The resin was washed with DMF (10×) and coupled with 0.5mmol of Boc-isonipecotic acid, HOBt and DIC in 2.5 ml of DMF over night.The resin was washed with DMF (10×) and reduced with 4 ml of a molarsolution of tin chloride dihydrate in DMF for 24 hours. The resin waswashed with DMF (5×), MeOH (5×), DCM (5×), DMF containing 5% ofdiisopropyl-ethylamine (1×) and DMF (3×). The final coupling with 1 mmolof phenylbutyric acid, 1-hydroxy-7-azabenzotriazole anddiisopropylcarbodiimide in 3 ml DMF was performed over night. Followingextensive washing of the resin with DMF, methanol and DCM and subsequentdrying, it was cleaved with 3 ml of 95% trifluoroacetic acid. The TFAsolution was evaporated and the residue was combined with the washingsof the resin with methanol. Evaporation yielded the crude title compoundwhich was purified by preparative HPLC using the standardacetonitrile/−water+0.1% TFA gradient and a Vidac C-18 column. The puresample had a M+1 ion at 704.3 in the mass spectrum and was homogenous byHPLC with a retention time of 24.12 minutes.

Example 144-(Piperidin-4-yl)carbonyl-1-{[2-(2-benzofuranoyl)amino]-4-[1-aminocarbonyl-2-(2-naphthyl)ethylamino]carbonylaminophenyl}homopiperazine

[0270]

[0271] This compound was prepared by the method of Example 13 using2-benzofuran-carboxylic acid in the final coupling step to give thetitle compound with M+1 ion at 702.1 and retention time of 25.5 minutes.

Example 154-(Piperidin-4-yl)carbonyl-1-{[2-(2-benzofuranoyl)amino]-4-[1-aminocarbonyl-2-cyclohexylethylamino]carbonylaminophenyl}homopiperazine

[0272]

[0273] This compound was prepared by the method of Example 13 usingFmoc-cyclohexylalanine in the initial coupling step and2-benzofurancarboxylic acid for the final acylation step to give thetitle compound with M+1 ion at 658.3 and retention time of 25.64minutes.

Example 164-(Piperidin-4-yl)carbonyl-1-[2-[(2-benzofuranoyl)amino]-4-[[(4-aminocarbonyl)cyclohexylmethylamino]carbonylaminophenyl]-homopiperazine

[0274]

[0275] This compound was prepared by the method of Example 13 usingFmoc-trans-4-aminomethylcyclohexanecarboxylic acid in the initialcoupling step and 2-benzofurancarboxylic acid for the final acylation togive the title compound with M+1 ion at 643.4 and retention time of21.84 minutes.

Example 17 4-(Methylaminomethyl)carbonyl-1-[2-[(2-benzofuranoyl)amino]-4-[[(4-aminocarbonyl)cyclohexylmethylamino]carbonylaminophenyl]homopiperazine

[0276]

[0277] This compound was prepared by the method of Example 13 usingFmoc-trans-4-aminomethylcyclohexanecarboxylic acid in the initialcoupling step and Boc-sarcosine for capping of the homopiperazine and2-benzofurancarboxylic acid for the final acylation to give the titlecompound with M+1 ion at 603.3 and retention time of 21.35 minutes.

Example 184-(Pyrrolidin-2-yl)carbonyl-1-[2-[(2-benzofuranoyl)amino]-4-[[(4-aminocarbonyl)cyclohexylmethylamino]carbonylamino]phenyl]homopiperazine

[0278]

[0279] This compound was prepared by the method of Example 13 usingFmoc-trans-4-aminomethylcyclohexanecarboxylic acid in the initialcoupling step, Boc-proline for capping of the homopiperazine and2-benzofurancarboxylic acid for the final acylation to give the titlecompound with M+1 ion at 629.3 and retention time of 22.12 minutes.

Example 194-(Piperidin-1-yl)-1-[2-[(2-benzofuranoyl)amino]-4-[[(4-amino-carbonyl)cyclohexylmethylamino]carbonylaminophenyl]-piperidine

[0280]

[0281] This compound was prepared by the method of Example 13 usingFmoc-trans-4-aminomethylcyclohexanecarboxylic acid in the initialcoupling step, 4-(1-piperidyl)piperidine to displace the fluorine and2-benzofurancarboxylic acid for the final acylation to give the titlecompound with M+1 ion at 600.3 and retention time of 22.5 minutes.

Example 20 4-(Piperidin-4-yl)carbonyl-1-[[2-(4-phenylbutanoyl)amino]-4-[1-aminocarbonyl-2-cyclohexylethylamino]carbonylaminophenyl]homopiperazine

[0282]

[0283] This compound was prepared by the method of Example 13 usingFmoc-L-cyclohexylalanine in the initial coupling step andBoc-isonipecotic acid for capping of the homopiperazine to give thetitle compound with M+1 ion at 659.4 and retention time of 23.97minutes.

Example 21 [4-(Piperidin-4-yl)carbonyl-1-[[2-(4-phenylbutanoyl)amino]-4-[(1-aminocarbonyl-2-(naphth-2-yl))ethylamino]-carbonylaminophenyl]homopiperazine

[0284]

[0285] This compound was prepared by the method of Example 13 usingFmoc-homophenylalanine in the initial coupling step to give the titlecompound with M+1 ion at 668.4 and retention time of 22.88 minutes.

[0286] Examples 22-25 describe the synthesis of sulfonamide compounds inaccordance with the compounds of the present invention.

Example 22N-(1-Aminocarbonyl-2-methylpropyl)-2-[(4-phenylmethyl)piperidin-1-yl]-5-[(2-pyrrolidinocarbonyl)amino]phenylsulfonamide

[0287]

[0288] Following generally the procedures described above, commercialPolystyrene-RAM resin (0.74 mmol/g) (Rapp Polymere, Tubingen, Germany,0.25 g) was slurried in dichloromethane, washed with DMF and treated for30 minutes with a mixture of piperidine and DMF (1:1 v/v). The resin waswashed with DMF (5×), DCM (5×) and DMF (3×) and then coupled with 0.5mmol of Fmoc-(L)-valine, 1-hydroxybenzotriazole anddiisopropylcarbodiimide in 3 ml DMF over night. The resin was washedwith DMF (5×) and treated with piperidine/DMF again for 30 minutes.After washing with DMF (5×) and DCM (10×), the coupling with 0.5 mmol of2-fluoro-5-nitrophenylsulfonyl chloride in 2 ml DCM and 1 mmol oflutidine was carried out over night. The resin was washed with DCM (5×)and DMF (5×) and treated with 3 ml of a 0.5 molar solution of4-benzyl-piperidine in DMF for 24 hours at room temperature. Afterwashing with DMF (10×), the nitro group was reduced by shaking the resinwith 4 ml of a 0.5 molar solution of tin chloride in DMF/acetic acid 1:1for 72 hours. The resin was washed with DMF (5×), MeOH (5×), DCM (5×),DMF containing 5% of diisopropylethylamine (1×) and DMF (3×). The finalcoupling with 1 mmol of 2-pyrolidinecarboxylic acid,1-hydroxy-7-azabenzotriazole and diisopropylcarbodiimide in 3 ml DMF wasperformed over night. Following extensive washing of the resin with DMF,methanol and DCM and subsequent drying, it was cleaved with 3 ml of 95%trifluoroacetic acid. The TFA solution was evaporated and the residuewas combined with the washings of the resin with methanol. Evaporationyielded the crude title compound which was purified by preparative HPLCusing the standard acetonitrile/water+0.1% TFA gradient and a Vydac C-18column. The pure sample had a M+1 ion at 542.3 in the mass spectrum andwas homogenous by HPLC with a retention time of 26.7 minutes.

Example 23N-(1-Aminocarbonyl-2-methylpropyl)-2-[(4-phenylmethyl)piperidin-1-yl]-5-[(4-piperdinocarbonyl)amino]phenylsulfonamide

[0289]

[0290] This compound was prepared by the method of Example 22 using4-piperidinecarboxylic acid in the final coupling step to give the titlecompound with a M+1 ion at 556.3 in the mass spectrum and a HPLCretention time of 26.2 minutes.

Example 241-[2-[N-(2-Aminocarbonyl-3-methylbutyl)sulfonamido]-5-[2-cinnamoylamino]]phenyl-4-cyclohexylpiperazine

[0291]

[0292] This compound was prepared by the method of Example 22 using1-cyclohexylpiperazine for displacement of the fluorine and cinnamicacid for the final acylation step to give the title compound with a M+1ion at 568.3 in the mass spectrum and a HPLC retention time of 24.63minutes.

Example 25N-[[(4-Aminocarbonyl)cyclohexylmethyl]amino]-[2-[(4-phenylmethyl)piperidin-1-yl]-5-[(2-pyrrolidinocarbonyl)-amino]phenyl]sulfonamide

[0293]

[0294] This compound was prepared by the method of Example 22 using Fmocprotected trans-4-aminomethylcyclohexanecarboxylic acid for the firstcoupling reaction to give the title compound with a M+1 ion at 582.3 inthe mass spectrum and a HPLC retention time of 25.31 minutes.

[0295] Protein Tyrosine Kinase Activity

[0296] The compounds 1-25 above were assayed for activity with respectto the Src protein tyrosine kinase by the fluorometric method describedin Measurement of the Protein Tyrosine Kinase Activity of c-Src UsingTime-Resolved Fluorometry of Europium Chelates, Braunwalder, A. F. etal., Analytical Biochemistry 238, 159-164 (1996), the disclosure ofwhich is incorporated herein by reference, using the materials andprocedures further specified below.

[0297] General Assay Method for Src-Kinase:

[0298] Materials:

[0299] Costar 384 Clear, non-treated, high-binding plates

[0300] Sigmapoly(Glu, Tyr) 4:1, ave. MW 35,000

[0301] Src Kinase (p60^(C-Src))

[0302] Sigma ATP (1.5 mM Stock Soln. in H₂O)

[0303] MES Buffer: 30 mM MES (pH 6.8)

[0304] 10 mM MgCl₂

[0305] MBI Buffer: (MES+0.4 mg/ml BSA+0.003% IGEPAL)

[0306] Wallac Eu-labelled anti-phosphotyrosine Antibody (CR04-100)

[0307] Coating Solution:

[0308] 22.5 mM Na₂CO₃ (pH 9.6)

[0309] 27.5 mM NaHCO₃

[0310] 0.9% NaCl

[0311] Antibody Dilution Buffer: (MES+3% BSA)

[0312] DELFIA® Wash Solution (TTBS):

[0313] 0.5 M NaCl

[0314] 20 mM Tris (pH7.4)

[0315] 0.15% Tween 20

[0316] DELFIA Enhancement Solution

[0317] Method:

[0318] The plates were coated with 0.1 mg/ml poly(Glu, Tyr) in CoatingSolution, 35 μl/well. It was let stand overnight at room temp. Theplates were then washed 3 times with MES (100 μl/wash).

[0319] Kinase Reaction Conditions:

[0320] Procedure (listed in order of addition):

[0321] 10 μl 200 μM A TP

[0322] 80 nl 5 mM test compound in DMSO

[0323] 10 μl 1:400 Src dilution in MBI

[0324] Final Reaction Conditions:

[0325] 1:8000 Src Kinase

[0326] 20 μM library compound (0.4% DMSO)

[0327] 100 μM ATP

[0328] 20 μL assay volume

[0329] 15 min. at room temp.

[0330] The reaction was stopped by aspiration, and then washed 3 timeswith MES (100 μl/wash). 20 μl 0.4 ng/μl of antibody in Antibody DilutionBuffer (final=8 ng Ab/well) was added and then incubated for 30 min. atRT. The antibody solution was removed by aspiration and then washed 3times with 1×DELFIA Wash Solution. 20 μl DELFIA enhancement solution wasadded and the plates were read on a Wallac Victor plate reader intime-resolved fluorescence mode using 340 nm excitation and 615 nmemission wavelengths.

[0331] The Src Kinase inhibitory activity of the compounds, given asIC50s (μM), are listed in Table 2. TABLE 2 Compound No. Activity (μMol,Delfia assay. IC50) Example 1 22 Example 2 23 Example 3 45 Example 4 18Example 5 12.5 Example 6 14 Example 7 13 Example 8 8.5 Example 9 17Example 10 15.5 Example 11 11 Example 12 18.5 Example 13 13 Example 142.75 Example 15 6.5 Example 16 36 Example 17 37 Example 18 19 Example 1922 Example 20 28 Example 21 22 Example 22 14 Example 23 12 Example 24 42Example 25 27.5

[0332] From these test results and the knowledge about the compoundsdescribed in the references in the section “Background of theInvention”, it would be apparent to the skilled artisan that thecompounds of the invention have utility in treating conditions whereselective inhibitory activity of an Src kinase is desirable. While theinvention has been described in detail, modifications to illustratedembodiments within the spirit and scope of the present invention, setforth in the appended claims, will be readily apparent to those of skillin the art.

What is claimed is:
 1. A compound, including enantiomers, stereoisomersand tautomers thereof, as well as pharmaceutically acceptable salts orsolvates of said compound, said compound having the general structureshown in Formula I:

wherein: m is an integer from 0 to 4; n is an integer from 1 to 6; R′ isa C₁-C₄ alkyl; R₁ is:

R₃ is selected from the group consisting of H, C₁-C₄ straight chainalkyl and C₁-C₄ branched alkyl; R₂ is selected from the group consistingof —(CH₂)_(p)—NH—C(═NH)NH₂; —(CH₂)_(p)— R₄and —(CH₂)_(q)—Ar₁, wherein pis an integer from 1 to 4; q is 0 or 1; R₄ is C₅-C₇ cycloalkyl; and Ar₁is selected from the group consisting of:

wherein R₅ is —NH₂ or phenyl.
 2. The compound claim 1, wherein m is 0and n is
 1. 3. The compound of claim 1, wherein R₁ is

where R₃ is as defined in claim
 1. 4. The compound of claim 1, whereinR₁ is:

where R₃ is as defined in claim
 1. 5. The compound of claim 1, whereinR₂ is —(CH₂)_(p)NHC(═NH)NH₂, where p is as defined in claim
 1. 6. Thecompound of claim 1, wherein R₂ is —(CH₂)_(p)—R₄ where p and R₄ are asdefined in claim
 1. 7. The compound of claim 1, wherein R₂ is—(CH₂)_(q)—Ar₁, wherein Ar₁ is:

where R₅ and q are as defined in claim
 1. 8. The compound of claim 1,wherein R₂ is —(CH₂)_(q)—Ar₁, wherein Ar₁ is:

where q is as defined in claim
 1. 9. The compound of claim 1, wherein R₂is —(CH₂)_(q)—Ar₁, wherein Ar₁ is:


10. The compound of claim 1 wherein the moiety:

is attached to the aromatic ring meta to the carbonyl on said ring. 11.The compound of claim 1 wherein the moiety:

is attached to the aromatic ring para to the carbonyl on said ring. 12.A pharmaceutical composition comprising as an active ingredient acompound of claim
 1. 13. A compound, including enantiomers,stercoisomers and tautomers thereof, as well as pharmaceuticallyacceptable salts or solvates of said compound, said compound having thegeneral structure shown in Formula II:

wherein R₁ is selected from the group consisting of H, straight chainC₁-C₆ alkyl; branched C₁-C₆ alkyl; —(CH₂)_(p)—Ar₁; and —(CH₂)_(p)—R₄,wherein p is 1 or 2; Ar₁ is phenyl or naphthyl optionally substitutedwith a straight chain or branched C¹-C⁶ alkyl group; and R₄ is C₅-C₇cycloalkyl; R₂ is selected from the group consisting of:

R₅ is selected from the group consisting of H, straight chain C₁-C₆alkyl; branched C₁-C₆ alky; R₃ is —(CH₂)_(q)—Ar₂ or —(CH═CH)-Phenyl,wherein q is an integer from 0 to 4; and Ar₂ is selected from the groupconsisting of:

Y is selected from the group consisting of:

with the proviso that when Y is any of the moieties:

then R₁ is H.
 14. The compound of claim 13, wherein X is:


15. The compound of claim 13, wherein X is:


16. The compound of claim 13, wherein R₁ is H.
 17. The compound of claim13, wherein R₁ is a straight chain C₁-C₆ alkyl or a branched C₁-C₆alkyl.
 18. The compound of claim 13, wherein R₁ is —(CH₂)_(p)—Ar₁, wherep and Ar₁ are as defined in claim
 13. 19. The compound of claim 13,wherein R₁ is —(CH₂)_(p)—R₄, where p and R₄ are as defined in claim 13.20. The compound of claim 13, wherein R₂ is:


21. The compound of claim 13, wherein R₂ is:


22. The compound of claim 13, wherein R₂ is:

where R₅ is as defined in claim
 13. 23. The compound of claim 13,wherein R₂ is:


24. The compound of claim 13, wherein R₂ is:


25. The compound of claim 13, wherein R₂ is:


26. The compound of claim 13, wherein R₃ is —(CH₂)_(q)—Ar₂, where q andAr₂ are as defined.
 27. The compound of claim 13, wherein R₃ is—(CH═CH)-Phenyl.
 28. The compound of claim 13, wherein Y is:


29. The compound of claim 13, wherein Y is:


30. The compound of claim 13, wherein Y is:


31. The compound of claim 13, wherein R₁ is isopropyl or isobutyl.
 32. Apharmaceutical composition comprising as an active ingredient a compoundof claim 13.